Abstract | OBJECTIVE: METHODS: Over an 18-month period, all cancer patients treated with ABLC at The Royal Shrewsbury Hospital were audited prospectively. Each patient received 100 mg of intravenous hydrocortisone 15-30 minutes prior to each ABLC infusion. The primary outcome was to determine the DDR rate per cycle of ABLC. RESULTS: A total of 275 cycles of ABLC (mean dosage 930.6 mg) were administered during the course of the study period, and 16.0% were associated with DDRs. The majority of reactions occurred following the first infusion of a cycle (15.3%; subsequent infusions: 2.9%). The most common DDRs were rigor (15.3%) and fever (12.7%). There was no significant difference in the DDR rate (17.2 vs. 15.5%) or types of reactions between ABLC-naïve and previously treated patients. The dosage of ABLC administered had no effect on the DDR rate. Female gender, being neutropenic and younger age were found to be predictive of having a DDR. CONCLUSIONS: The audit demonstrates that premedication with hydrocortisone results in a low incidence of DDRs following ABLC. The main limitation of this study is the lack of a randomised control group.
|
Authors | Nigel O'Connor, Ann Borley |
Journal | Current medical research and opinion
(Curr Med Res Opin)
Vol. 25
Issue 3
Pg. 749-54
(Mar 2009)
ISSN: 1473-4877 [Electronic] England |
PMID | 19196219
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- liposomal amphotericin B
- Amphotericin B
- Hydrocortisone
|
Topics |
- Amphotericin B
(administration & dosage)
- Female
- Humans
- Hydrocortisone
(administration & dosage)
- Male
- Middle Aged
- Prospective Studies
|